


## L-Tyrosine-<sup>13</sup>C<sub>6</sub>

<b>Cat. No.:</b>	HY-N0473S2		
<b>CAS No.:</b>	201595-63-3		
<b>Molecular Formula:</b>	C <sub>3</sub> <sup>13</sup> C <sub>6</sub> H <sub>11</sub> NO <sub>3</sub>		
<b>Molecular Weight:</b>	187.14		
<b>Target:</b>	Endogenous Metabolite		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

1M HCl : 33.33 mg/mL (178.10 mM; ultrasonic and adjust pH to 1 with HCl)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	5.3436 mL	26.7180 mL	53.4359 mL
	5 mM	1.0687 mL	5.3436 mL	10.6872 mL
	10 mM	0.5344 mL	2.6718 mL	5.3436 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

L-Tyrosine-<sup>13</sup>C<sub>6</sub> is the <sup>13</sup>C-labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA